6288-93-3

Usage

Uses

Used in Pharmaceutical Industry:
6-(Propylthio)purine is used as a potential therapeutic agent for various medical conditions, including viral infections and cancer. Its antiviral and anticancer properties make it a promising candidate for the development of new treatments in these areas.
Used in Research and Development:
6-(Propylthio)purine serves as a research tool in studying purine metabolism and as a biochemical probe in cell biology studies. Its unique structure and properties allow researchers to gain insights into the mechanisms of purine-related processes and contribute to the advancement of scientific knowledge in these fields.

InChI:InChI=1/C8H10N4S/c1-2-3-13-8-6-7(10-4-9-6)11-5-12-8/h4-6H,2-3H2,1H3

Upstream product

• 50-44-2 6H-purine-6-thione 
• 106-94-5 propyl bromide 
• 107-03-9 1-thiopropane 
• 87-42-3 6-chloro-7H-purine 
• 157930-09-1 6-Mercaptopurine 

Downstream Products

• 82499-12-5 6-propylsulfonylpurine 
• 120-73-0 purine 

Relevant academic research and scientific papers

The discovery of purine-based agents targeting triple-negative breast cancer and the αB-crystallin/VEGF protein–protein interaction

Oestrogen receptor-negative breast cancer, particularly subtypes such as triple-negative breast cancer (TNBC, around 10–15% of cases), are characterised by poor long-term survival, poor response to therapy and early progression to metastasis. Purine-based compounds represent a privileged scaffold in anticancer drug design, with several clinically approved and experimental agents in clinical development comprising a purine core structure. In this study, a series of new purine-based compounds were synthesised; seven of the new analogues were found to significantly reduce the in vitro viability of TNBC cell lines (MDA-MB-231 and MDA-MB-436) with IC50 values of ≤50 μM. In previous work, we have proposed a new concept for targeting angiogenesis driving TNBC progression, by disrupting the protein–protein interaction between the molecular chaperone αB-crystallin (CRYAB) and VEGF. Since previous clinical studies applying anti-VEGF therapy to TNBC patients have met with limited success, we were interested to test our most promising purine analogues against CRYAB/VEGF, using a custom-designed cell-based CRYAB/VEGF165 interaction assay platform. Analogues 4e and 4f significantly reduced the interaction between CRYAB/VEGF165, and compound 4e (100 μM) was also found to decrease the levels of soluble VEGF expressed by MDA-MB-231 cells by 40%. In conclusion, these promising early activity profiles warrant further investigation to validate this concept.

Modification of thionucleobases in ionic liquids

A simple method was established for the preparation of thio-substituted thionucleobases using room temperature ionic liquids (RTILs) such as 1-butyl-3-methylimidazolium trifluoroacetate [BMIM]+[CF3COO]- and 1-methoxyethyl-3-methylimidazolium trifluoroacetate [MeOEtMIM]+[CF3COO]- as solvents and catalysts without any other catalyst. These reactions proceeded efficiently in RTILs with excellent yield of products. RTILs can be recycled and reused effectively without further purification.